These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38899493)

  • 21. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
    Gion M; García-Mosquera JJ; Pérez-García JM; Peg V; Ruiz-Borrego M; Stradella A; Bermejo B; Guerrero JA; López-Montero L; Mancino M; Rodríguez-Morató J; Antonarelli G; Sampayo-Cordero M; Llombart-Cussac A; Cortés J
    Breast Cancer Res Treat; 2024 Jun; 205(3):589-598. PubMed ID: 38456970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
    Chumsri S; Jeter S; Jacobs LK; Nassar H; Armstrong DK; Emens LA; Fetting JH; Lange JR; Riley C; Tsangaris TN; Wolff AC; Zellars R; Zhang Z; Stearns V
    Clin Breast Cancer; 2010 Feb; 10(1):40-5. PubMed ID: 20133257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
    Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
    Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant Treatment for a cT4cN+ HER2+ Breast Cancer: Case Report of a Therapeutic Success.
    Gunnellini M; Tornincasa A; Montedoro M; Caprodossi A; Prosperi E; Peverini M; Sarti AM; Aiuti S; Morini T
    Anticancer Res; 2024 Jun; 44(6):2755-2758. PubMed ID: 38821608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
    Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
    Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
    Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
    Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation Between Preoperative Radiological and Postoperative Pathological Tumor Size in Patients With HER2
    Falcone V; Reiser E; Grula L; Bago-Horvath Z; Stolz M; Catic A; Deutschmann C; Singer C; Pfeiler G
    Clin Breast Cancer; 2022 Feb; 22(2):149-160. PubMed ID: 34229944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
    Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS
    Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
    van der Voort A; Louis FM; van Ramshorst MS; Kessels R; Mandjes IA; Kemper I; Agterof MJ; van der Steeg WA; Heijns JB; van Bekkum ML; Siemerink EJ; Kuijer PM; Scholten A; Wesseling J; Vrancken Peeters MTFD; Mann RM; Sonke GS;
    Lancet Oncol; 2024 May; 25(5):603-613. PubMed ID: 38588682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
    Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
    Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
    Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
    J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3-year invasive disease-free survival with chemotherapy de-escalation using an
    Pérez-García JM; Cortés J; Ruiz-Borrego M; Colleoni M; Stradella A; Bermejo B; Dalenc F; Escrivá-de-Romaní S; Calvo Martínez L; Ribelles N; Marmé F; Cortés A; Albacar C; Gebhart G; Prat A; Kerrou K; Schmid P; Braga S; Di Cosimo S; Gion M; Antonarelli G; Popa C; Szostak E; Alcalá-López D; Gener P; Rodríguez-Morató J; Mina L; Sampayo-Cordero M; Llombart-Cussac A;
    Lancet; 2024 Apr; 403(10437):1649-1659. PubMed ID: 38582092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
    Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.